Discontinued — last reported Q2 '24
Non-Current Assets
AFS Securities
Vertex Pharmaceuticals AFS Securities decreased by 58.3% to $25.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 65.3%, from $72.10M to $25.00M. Over 4 years (FY 2020 to FY 2024), AFS Securities shows a downward trend with a -5.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ2 2024
Parent metricTotal investment securities
How to read this metric
An increase reflects capital allocation toward investment portfolios, while a decrease may signal portfolio rebalancing or asset liquidation.
Detailed definition
Available-for-sale securities are debt or equity investments that are not classified as trading or held-to-maturity, and...
Peer comparison
Common in the investment portfolios of banks and insurance companies.
Metric ID:
fin_afs_securitiesHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.13M | $62.74M | $64.80M | $55.70M | $4.50M | $14.10M | $112.20M | $1.08B | $1.36B | $1.70B | $72.10M | $72.10M | $72.10M | $72.10M | $72.10M | $60.00M | $60.00M | $25.00M |
| QoQ Change | — | +78.6% | +3.3% | -14.0% | -91.9% | +213.3% | +695.7% | +863.9% | +25.5% | +25.2% | -95.8% | +0.0% | +0.0% | +0.0% | +0.0% | -16.8% | +0.0% | -58.3% |
| YoY Change | — | — | — | — | -87.2% | -77.5% | +73.1% | >999% | >999% | >999% | -35.7% | -93.3% | -94.7% | -95.8% | +0.0% | -16.8% | -16.8% | -65.3% |
Range$4.50M – $1.70B
CAGR-7.7%
Avg YoY Growth>999%
Median YoY Growth-26.3%
AFS Securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's afs securities?
- Vertex Pharmaceuticals (VRTX) reported afs securities of $25.00M in Q3 2025.
- How has Vertex Pharmaceuticals's afs securities changed year-over-year?
- Vertex Pharmaceuticals's afs securities decreased by 65.3% year-over-year, from $72.10M to $25.00M.
- What is the long-term trend for Vertex Pharmaceuticals's afs securities?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's afs securities has grown at a -5.3% compound annual growth rate (CAGR), from $89.80M to $72.10M.
- What does afs securities mean?
- Investments in securities that are held for potential sale and marked to fair market value.